Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.

Abstract excerpt

Major causes of morbidity and mortality in polycythemia vera (PV) and essential thrombocythemia (ET) are represented by thrombosis and bleeding, progression to myelofibrosis and transformation to acute leukemia. Myelosuppressive therapy, preferentially with hydroxyurea, can reduce the rate of vascular complications, but there is some concern about an increased rate of leukemic transformation with this agent....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aspirin
• Share to Hydroxyurea
• Share to Interferon-alpha